Physician Assistant · Chula Vista, CA
NPI
1942914510
Since 2023
Specialty
Physician Assistant
Code 363A00000X
Group practices
1
Medicare group memberships
Hospitals
0
Hospital affiliations
340 4th Ave Ste 7a
Chula Vista, CA, 91910
Phone (619) 691-0388
Groups this clinician bills Medicare through
Medicare paid, 2024
$24K
346 services
Medicare patients, 2024
160
Average age 73
Drug cost, 2024
$3.5M
5,884 prescriptions
Company payments, 2025
$70.15
From 2 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Myunghee R Lee was code 99214 (office e&m - established), 146 times for 93 patients. In total Myunghee R Lee billed 346 services in 9 codes, and Medicare paid $24K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2024-11-11.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Office | 146 | 93 | $82.56 | $12K |
| 99443 Telephone Services | Office | 82 | 58 | $78.11 | $6,405 |
| 95251 Test - Miscellaneous | Office | 62 | 33 | $23.70 | $1,470 |
| 99442 Telephone Services | Office | 27 | 25 | $63.48 | $1,714 |
| 99213 Office E&M - Established | Office | 15 | 14 | $63.60 | $954 |
By year: 2023 $18K for 217 services; 2024 $24K for 346 services.
Medicare prescription drug claims, 2024
In 2024, the drug Myunghee R Lee prescribed most often to Medicare patients was Ozempic (Semaglutide), with 727 prescriptions and refills. In total Myunghee R Lee wrote 5,884 Medicare prescriptions that cost $3.5M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Ozempic Semaglutide | 727 | 978 | 150 | $901K |
| Jardiance Empagliflozin | 511 | 899 | 137 | $501K |
| Trulicity Dulaglutide | 508 | 710 | 128 | $667K |
| Levothyroxine Sodium Generic | 296 | 762 | 105 | $3,766 |
| Metformin Hcl Generic | 251 | 680 | 87 | $2,244 |
| Lantus Solostar Insulin Glargine,hum.Rec.Anlog | 218 | 496 | 83 | $23K |
| Mounjaro Tirzepatide | 167 | 184 | 33 | $191K |
| Nano 2nd Gen Pen Needle Pen Needle, Diabetic | 166 | 394 | 70 | $16K |
| Farxiga Dapagliflozin Propanediol | 162 | 354 | 45 | $191K |
| Methimazole Generic | 159 | 289 | 36 | $1,207 |
| Humalog Kwikpen U-100 Insulin Lispro | 140 | 319 | 60 | $29K |
| Rybelsus Semaglutide | 132 | 225 | 37 | $203K |
| Atorvastatin Calcium Generic | 122 | 267 | 37 | $1,155 |
| Basaglar Kwikpen U-100 Insulin Glargine,hum.Rec.Anlog | 97 | 223 | 36 | $35K |
| Humalog Insulin Lispro | 79 | 130 | 27 | $14K |
Brand drugs: 3,834 claims; generic drugs: 1,435 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Myunghee R Lee $70.15 ($70.15 in general payments such as food, travel and fees) from 2 companies. The largest payer was Dexcom, Inc. with $45.53.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.